ArticleCureus2026
Idiopathic Acquired Hemophilia A With High-Titer Factor VIII Inhibitor in an Elderly Patient: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acquired hemophilia A is a rare autoimmune bleeding disorder caused by neutralizing autoantibodies against factor VIII. It typically affects older adults and may present with spontaneous mucocutaneous bleeding, extensive ecchymoses, soft-tissue hematomas, and isolated prolongation of the activated partial thromboplastin time. We report the case of an 84-year-old woman with hypertension, hyperlipidemia, and anxiety who presented with several weeks of spontaneous nontraumatic bruising, fatigue, and exertional dyspnea. Initial evaluation revealed severe normocytic anemia, isolated aPTT prolongation, lack of correction on a mixing study, factor VIII activity <5%, and a high-titer factor VIII inhibitor of 470 Bethesda Units. Lupus anticoagulant testing was initially positive, while anticardiolipin and anti-β2-glycoprotein I antibodies were negative. The patient developed a right upper extremity hematoma and required a packed red blood cell transfusion. Immunosuppressive therapy with high-dose prednisone and weekly rituximab was initiated, with subsequent clinical improvement, normalization of aPTT, recovery of factor VIII activity, and disappearance of the inhibitor during follow-up. This case highlights the importance of considering acquired hemophilia A in elderly patients with spontaneous bleeding and isolated aPTT prolongation, even in the presence of transient lupus anticoagulant positivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.